Pharmaceutical company Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals, announced on Saturday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Imuldosa (DMB-3115), a biosimilar to Stelara (ustekinumab), marketed by Janssen Biotech, a Johnson & Johnson subsidiary.
Ustekinumab is a monoclonal antibody targeting cytokines involved in inflammatory and immune responses.
The CHMP recommendation bolsters Accord Healthcare's position in the autoimmune market, where it already has several specialty brands. This development aligns with Accord's strategy to expand its specialty portfolio. The company has 10 additional biosimilars in development, reinforcing its commitment to improving patient access to value-based medicines.
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date